|
102 Companies |
|
136 Products |
|
136 Products |
|
123 Mechanisms of Action |
|
5 Trials |
|
1111 News |
|
| «12345678910111213...1617» |
- Trial primary completion date: FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) - Nov 10, 2016
P2, N=25, Active, not recruiting, Sponsor: David M. Schuster, MD
Trial primary completion date: Oct 2016 --> Oct 2017
- | praziquantel / Generic mfg.
Trial completion: Bilhvax3: Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium (clinicaltrials.gov) - Nov 8, 2016
P3, N=250, Completed, Sponsor: Institut National de la Sant
Trial primary completion date: Oct 2016 --> Oct 2017 Recruiting --> Completed
- budesonide inhalation suspension / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Nov 8, 2016
P1, N=30, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016
- | Trial completion, Enrollment change, Trial primary completion date: Monitor-AF;EPEUHM: Management of New-Onset Postoperative Atrial Fibrillation (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=23, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016 Active, not recruiting --> Completed | N=50 --> 23 | Trial primary completion date: Oct 2016 --> Mar 2016
- Trial primary completion date, Metastases: Cyto-Cog: Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed | N=50 --> 23 | Trial primary completion date: Oct 2016 --> Mar 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- chloroquine phosphate / Generic mfg.
Trial completion: CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS (clinicaltrials.gov) - Oct 26, 2016
P4, N=61, Completed, Sponsor: University of Sao Paulo General Hospital
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Completed
- || Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Trial primary completion date: Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) - Oct 21, 2016
P3, N=43, Completed, Sponsor: George W. Burke
Active, not recruiting --> Completed Suspended --> Completed | Trial primary completion date: Feb 2017 --> Oct 2016
- 5-fluorouracil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Surgery: OCUM: Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=1051, Completed, Sponsor: Johannes Gutenberg University Mainz
Suspended --> Completed | Trial primary completion date: Feb 2017 --> Oct 2016 Recruiting --> Completed | N=782 --> 1051 | Trial primary completion date: Jun 2016 --> Sep 2016
- ||||| VivaGel (astodrimer vaginal) / Starpharma
Enrollment closed, Trial primary completion date: Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) (clinicaltrials.gov) - Oct 17, 2016
P3, N=620, Active, not recruiting, Sponsor: Starpharma Pty Ltd
Recruiting --> Completed | N=782 --> 1051 | Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Jan 2017
- Stivarga (regorafenib) / Bayer
Enrollment change, Trial withdrawal, Metastases: Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment (clinicaltrials.gov) - Oct 12, 2016
P2, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Jan 2017 N=80 --> 0 | Recruiting --> Withdrawn
- Trial completion, Enrollment change: MyLIFE: My Lifestyle Intervention of Food and Exercise (clinicaltrials.gov) - Sep 30, 2016
P=N/A, N=87, Completed, Sponsor: University of Florida
N=80 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | N=120 --> 87
- letrozole / Generic mfg.
Trial primary completion date: Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: New York Medical College
Active, not recruiting --> Completed | N=120 --> 87 Trial primary completion date: Dec 2012 --> Sep 2018
- | Trial completion: Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (clinicaltrials.gov) - Sep 23, 2016
P1, N=49, Completed, Sponsor: Dr. Reddy's Laboratories Limited
Trial primary completion date: Dec 2012 --> Sep 2018 Recruiting --> Completed
- Enrollment change: PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (clinicaltrials.gov) - Sep 20, 2016
P2, N=1500, Recruiting, Sponsor: Phoenix Molecular Imaging
Recruiting --> Completed N=500 --> 1500
- Enrollment change, Trial withdrawal, Surgery: Regional Anesthesia in Colon Rectal Surgery (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=0, Withdrawn, Sponsor: The Cleveland Clinic
N=500 --> 1500 N=2500 --> 0 | Recruiting --> Withdrawn
- Trial primary completion date: Regional Anesthesia and Lung Cancer Recurrence (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=67, Terminated, Sponsor: The Cleveland Clinic
N=2500 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Dec 2015 --> Aug 2015
- || Dificid (fidaxomicin) / Merck (MSD), Astellas
Trial primary completion date: DAFNE: Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=300, Recruiting, Sponsor: Astellas Pharma S.A.S.
Trial primary completion date: Dec 2015 --> Aug 2015 Trial primary completion date: Jun 2016 --> Jun 2017
- Trial completion, Enrollment change, Trial primary completion date: PseudIgY: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis (clinicaltrials.gov) - Sep 1, 2016
P1/2, N=14, Completed, Sponsor: Immunsystem AB
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012
- Trial completion: REVERSEII: Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism (clinicaltrials.gov) - Sep 1, 2016
P4, N=2779, Completed, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012 Active, not recruiting --> Completed
- ||||||| Civacir (hepatitis C immune globulin) / ADMA Biologics, Kedrion
Trial completion: Civacir (clinicaltrials.gov) - Sep 1, 2016
P3, N=80, Completed, Sponsor: Biotest Pharmaceuticals Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection (clinicaltrials.gov) - Sep 1, 2016
P2, N=9, Completed, Sponsor: MemorialCare Health System
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016
- everolimus / Generic mfg.
Trial completion: The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation (clinicaltrials.gov) - Aug 31, 2016
P3, N=18, Completed, Sponsor: Hospital Vall d'Hebron
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016 Active, not recruiting --> Completed
- Dexilant (dexlansoprazole) / Takeda
Enrollment change, Trial termination, Trial primary completion date: Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation (clinicaltrials.gov) - Aug 24, 2016
P4, N=6, Terminated, Sponsor: Takeda
Active, not recruiting --> Completed N=150 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Apr 2016; Business Decisions; No Safety Concerns
- docetaxel / Generic mfg.
Trial primary completion date, Combination therapy, Surgery, Metastases: Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer (clinicaltrials.gov) - Jul 29, 2016
P2, N=100, Recruiting, Sponsor: Centre Jean Perrin
N=150 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Apr 2016; Business Decisions; No Safety Concerns Trial primary completion date: Sep 2010 --> Jan 2017
- | escitalopram / Generic mfg.
Enrollment closed, Trial primary completion date, Head-to-Head: Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial (clinicaltrials.gov) - Jul 28, 2016
P3, N=245, Active, not recruiting, Sponsor: University of Sao Paulo
Trial primary completion date: Sep 2010 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jul 2016
- Trial completion, Enrollment change, Trial primary completion date: A Pilot Study Using Weightloss and Exercise to Prevent Recurring Gestational Diabetes in Obese Women (clinicaltrials.gov) - Jul 26, 2016
P=N/A, N=12, Completed, Sponsor: California Polytechnic State University-San Luis Obispo
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jul 2016 Enrolling by invitation --> Completed | N=60 --> 12 | Trial primary completion date: Apr 2016 --> Jun 2014
- Votrient (pazopanib) / Novartis, BeiGene
Biomarker: Neoadjuvant Pazopanib in Renal Cell Carcinoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=21, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Enrolling by invitation --> Completed | N=60 --> 12 | Trial primary completion date: Apr 2016 --> Jun 2014 Trial primary completion date: Jun 2016 --> Jun 2017
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial termination, Trial primary completion date: Cimzia Versus Mesalamine for Crohn's Recurrence (clinicaltrials.gov) - Jul 19, 2016
P4, N=10, Terminated, Sponsor: Milton S. Hershey Medical Center
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; Lack of accrual
- azacitidine / Generic mfg.
Enrollment change, Trial withdrawal: UPCI 13-165: Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (clinicaltrials.gov) - Jul 19, 2016
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; Lack of accrual N=35 --> 0 | Recruiting --> Withdrawn
- ||||||| goserelin acetate / Generic mfg.
Trial completion, Enrollment change: ELAAT: Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy (clinicaltrials.gov) - Jul 13, 2016
P3, N=79, Completed, Sponsor: Ontario Clinical Oncology Group (OCOG)
N=35 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | N=1100 --> 79
- | bupropion / Generic mfg.
Trial completion: Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking (clinicaltrials.gov) - Jul 11, 2016
P3, N=1708, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=1100 --> 79 No longer recruiting --> Completed
- Trial completion: ADLINE: Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation (clinicaltrials.gov) - Jun 27, 2016
P=N/A, N=90, Completed, Sponsor: Deutsches Herzzentrum Muenchen
No longer recruiting --> Completed Recruiting --> Completed
- Enrollment closed, Enrollment change: SUIVICOL: Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=106, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Recruiting --> Active, not recruiting | N=300 --> 106
- rivaroxaban / Generic mfg.
Enrollment closed, Trial primary completion date: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer (clinicaltrials.gov) - Jun 23, 2016
P4, N=127, Active, not recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting | N=300 --> 106 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016
- Enrollment closed, Enrollment change: Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection (clinicaltrials.gov) - Jun 22, 2016
P2, N=9, Active, not recruiting, Sponsor: MemorialCare Health System
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Active, not recruiting | N=46 --> 9
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial suspension: Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) - Jun 21, 2016
P3, N=43, Suspended, Sponsor: George W. Burke
Recruiting --> Active, not recruiting | N=46 --> 9 Active, not recruiting --> Suspended
- cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Trial primary completion date, Surgery: Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery (clinicaltrials.gov) - Jun 21, 2016
P1, N=1, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Suspended Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016
- | Enrollment change: CLOSE: Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (clinicaltrials.gov) - Jun 19, 2016
P3, N=664, Active, not recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016 N=900 --> 664
- | gemcitabine / Generic mfg.
Enrollment closed: Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Jun 10, 2016
P2/3, N=116, Active, not recruiting, Sponsor: Seoul National University Hospital
N=900 --> 664 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2017 | Recruiting --> Active, not recruiting
- chloroquine phosphate / Generic mfg., primaquine / Generic mfg.
Trial completion, Enrollment change: Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan (clinicaltrials.gov) - May 27, 2016
P=N/A, N=24, Completed, Sponsor: Menzies School of Health Research
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2017 | Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=50 --> 24
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia (clinicaltrials.gov) - May 19, 2016
P1, N=10, Completed, Sponsor: University of New Mexico
Active, not recruiting --> Completed | N=50 --> 24 Recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jul 2014
- | Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: SELEBLAT: Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer (clinicaltrials.gov) - May 13, 2016
P3, N=276, Completed, Sponsor: Katholieke Universiteit Leuven
Recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jul 2014 Recruiting --> Completed | N=900 --> 276 | Initiation date: Jun 2008 --> Sep 2009 | Trial primary completion date: Oct 2014 --> Dec 2015
- sevoflurane / Generic mfg.
Trial withdrawal: ECA/R: Regional Anesthesia and Endometrial Cancer Recurrence (clinicaltrials.gov) - May 9, 2016
P3, N=0, Withdrawn, Sponsor: The Cleveland Clinic
Recruiting --> Completed | N=900 --> 276 | Initiation date: Jun 2008 --> Sep 2009 | Trial primary completion date: Oct 2014 --> Dec 2015 Terminated --> Withdrawn
- cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Enrollment change, Surgery: Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery (clinicaltrials.gov) - May 3, 2016
P1, N=1, Active, not recruiting, Sponsor: Mayo Clinic
Terminated --> Withdrawn Recruiting --> Active, not recruiting | N=13 --> 1
- Trial completion, Trial primary completion date: Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition? (clinicaltrials.gov) - May 3, 2016
P=N/A, N=50, Completed, Sponsor: Atlantic Health System
Recruiting --> Active, not recruiting | N=13 --> 1 Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Apr 2015
- anastrozole / Generic mfg.
Trial completion: Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Apr 27, 2016
P4, N=70, Completed, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Apr 2015 Recruiting --> Completed
- | Trial completion: hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP) (clinicaltrials.gov) - Apr 25, 2016
P3, N=1095, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: J-STARS Echot: Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo) (clinicaltrials.gov) - Apr 25, 2016
P3, N=854, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | pravastatin / Generic mfg.
Trial completion: Japan Statin Treatment Against Recurrent Stroke (J-STARS) (clinicaltrials.gov) - Apr 25, 2016
P3, N=1578, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=754, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2016